Drugs / HyperAcute®-Lung Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01774578 | Feb 2013 → May 2016 | non-small cell lung carcinoma | NewLink Genetics Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HyperAcute-Lung Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01774578 ↗ |
| Modality | Cell therapy | “immunotherapy consisting of three types of modified lung cancer cells” NCT01774578 ↗ |